Provention Bio, Inc.

Provention Bio, Inc.

Provention Bio, Inc.

Overview
Date Founded

2016

Headquarters

55 Broad Street,2nd floor,Red Bank, NJ 07701

Type of Company

Public

Employees (Worldwide)

19

Industries

Pharmaceuticals
Biotechnology
Medical Support Services
Hospitals & Patient Services

Company Description

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D); PRV-015 for the treatment of gluten-free diet non-responding celiac disease; PRV-6527 for Crohn’s disease; PRV-3279 for the treatment of lupus; and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Lebanon, NJ.

Contact Data
Trying to get in touch with decision makers at Provention Bio, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer & Co-Founder

Chief Scientific Officer & Co-Founder

Chief Financial Officer

Chief Commercial Officer

Chief Medical Officer

Chief Legal Officer

Senior Vice President-Research & Early Development

Senior Vice President of Clinical Development

Head, Medical Affairs Activities-Teplizumab

Vice President of Investor Relations

Board of Directors

President at Pirus Biological & Vaccine Consulting

Co-Founder, Chief Executive Officer & President at Sonoma Biotherapeutics, Inc.

Former Executive Vice President & Chief Commercial Officer at Vertex Pharmaceuticals, Inc.

Managing Director at Bain Capital Private Equity LP

Director at Corbus Pharmaceuticals, Inc.

Chief Executive Officer & Co-Founder at Provention Bio, Inc.

Principal-Drug & Biological Products at Greenleaf Health Inc.

Paths to Provention Bio, Inc.
Potential Connections via
Relationship Science
You
Provention Bio, Inc.
Owners & Shareholders
Details Hidden

Sessa Capital seeks to outperform the broad equity indices over each investment cycle as well as over the life of the funds. The firm utilizes a value and special situation investment approach. They invest client assets in a wide range of asset classes and geographies. On the short side, Sessa Capital expects to sell short equities, fixed income, and other financial instruments that reflect failing businesses, troubled operations, unsustainable capital structures, rich valuations, accounting irregularities, suspect promotions, and theme based shorts, among others. Additionally, shorts may be used to hedge certain exposures on the long side or to hedge the overall portfolio. On the long side, the firm expects to mostly purchase equity securities and securities that can provide equity-like returns.

Details Hidden

Venrock Associates invest in companies located in the US. The firm targets companies operating in the fields of intelligent enterprise & AI, security & infrastructure, fintech, healthcare IT, defense & Aerospace, robotics & autonomy and consumer sectors. They provides financing for early and later stage capital requirements.

Details Hidden

DG Capital Management's investment objective is to achieve above average long-term rates of return, primarily through capital appreciation and income, while also attempting to preserve capital and mitigate risk through diversification of investments and hedging activities. It is expected that most of the funds assets will be invested in publicly-traded equity securities. The fund seeks to purchase securities that are priced at a significant discount to intrinsic value. In addition, the fund may short securities or engage in other hedging transactions through options or other derivatives to offset risk. The fund also expects to invest a portion of its assets in special situations, where an event is expected to cause appreciation in the price of the security, as opposed to relying exclusively on business fundamentals or general market movements. DG Capital Management may invest in companies of any market-cap, geographic location or market sector. The funds investment position will generally be long-biased although it may be market neutral or have significant holdings in cash, depending on investment conditions.

Recent Transactions
Details Hidden

Provention Bio, Inc. issued USD Common Stock

Details Hidden

Provention Bio, Inc. issued USD Common Stock

Details Hidden

Provention Bio, Inc. issued USD Common Stock

Transaction Advisors
Auditor

Advised onProvention Bio, Inc. issued USD Common Stock

Legal Advisor

Advised onProvention Bio, Inc. issued USD Common Stock

Underwriter

Advised onProvention Bio, Inc. issued USD Common Stock

Professional

Advised onProvention Bio, Inc. issued USD Common Stock

Managing Director, BioPharma

Advised onProvention Bio, Inc. issued USD Common Stock

Chair, Life Sciences Practice

Advised onProvention Bio, Inc. issued USD Common Stock

Advisors & Consultants
Publicist

Executive Vice President & Chief Operating Officer at Tiberend Strategic Advisors, Inc.

Publicist

Senior Vice President at Tiberend Strategic Advisors, Inc.

Advisor

Managing Director at Argot Partners LLC

Clients

Huadong Medicine Co., Ltd. engages in the production and sale of antibiotics, proprietary Chinese medicine, chemical synthetic medicine, and genetic engineering drugs. It involves in wholesale, retail, and distribution of Chinese and western medicine, Chinese herbal medicine, medical apparatus and instruments. Its products include Chinese medicine, drug immune agents, endocrine drugs, gastrointestinal agents, active pharmaceutical ingredient, hepatitis B medicine, and antineoplastic agents. The company was founded on March 31, 1993 and is headquartered in Hangzhou, China.

Key Stats and Financials As of 2020
Market Capitalization
$455M
Total Enterprise Value
$768M
Earnings Per Share
$-1.88
Revenue
$0
Total Equity
$111M
Total Debt
$787K
EBITDA
$-99.7M
Net Profit
$-98.6M
TEVNet Income
-7.79x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
0%
Investors
Details Hidden

JDRF invests in companies located in the US. The firm focuses on pharma sectors such as advance drugs, devices, diagnostics and vaccines. The firm provides financing for early stage capital requirements.

Details Hidden

Founded in 1997, MDB Capital Group LLC is a microcap investment bank and SEC-registered broker-dealer headquartered in Santa Monica, California. MDB provides financial services to privately-held companies and emerging growth public companies. They also provide research to institutional asset management firms, hedge funds, mutual funds and high net-worth individuals. The firm is a member of FINRA.

Details Hidden

Chief Scientific Officer & Co-Founder at Provention Bio, Inc.

Suppliers
Amgen, Inc. Hospitals & Patient Services | Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

MacroGenics, Inc. Industrial Machinery & Manufacturing | Rockville, MD

MacroGenics is a leader in the discovery and development of innovative medicinces that utilize our next generation antibody-based technologies. Our team of 150+ dedicated individuals is advancing a pipeline of product candidates to treat patients with cancer and other serious, complex diseases. Our products and platforms have attracted multiple partnerships with leading pharmaceutical companies around the globe. Our innovative product candidates leverage our fully-integrated capabilities around the discovery, development, and production of antibodies and incorporate three proprietary technology platforms: Our Dual-Affinity Re-Targeting (DART™) platform enables us to design candidate therapeutics that target multiple disease-causing cells or redundant disease-associated pathways with a single molecule; Our Fc Optimization platform enhances the natural immune system's ability to mediate killing of cancer cells; and Our Cancer Stem Cell platform provides new approaches to target cancers unresponsive to current therapy.

AGC, Inc. (Japan) Other Manufacturing | Tokyo, Japan

AGC, Inc. engages in the manufacture and sale of glass, electronic materials, and chemicals. It operates through the following segments: Glass, Electronics, Chemicals, Ceramics and Other. The Glass segment provides security glass, fire-resistant glass, heat insulating glass, and automotive glass. The Electronics segment offers glass for display panels, optical thin film products, opto-electronic materials, synthetic quartz products, semiconductor components, and lighting products. The Chemicals segment deals with chlor-alkali and urethane products, water and oil repellents, solvents, gases, and specialty chemicals. The Ceramics and Other segment includes ceramic products, logistics, and financial services. The company was founded by Toshiya Iwasaki on September 8, 1907 and is headquartered in Tokyo, Japan.

Competitors
Abbott Laboratories Pharmaceuticals - Abbott Park, Illinois

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

AstraZeneca Plc Pharmaceuticals - Cambridge, United Kingdom

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

GlaxoSmithKline Plc Pharmaceuticals - Brentford, Gbr

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Provention Bio, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Provention Bio, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Provention Bio, Inc..